Literature DB >> 25624456

GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: functional analysis of the p.Arg396Gln mutation.

Xabier Cortés-Lavaud1, Manuel F Landecho2, Miren Maicas3, Leire Urquiza3, Juana Merino4, Isabel Moreno-Miralles3, María D Odero5.   

Abstract

Germline GATA2 mutations have been identified as the cause of familial syndromes with immunodeficiency and predisposition to myeloid malignancies. GATA2 mutations appear to cause loss of function of the mutated allele leading to haploinsufficiency; however, this postulate has not been experimentally validated as the basis of these syndromes. We hypothesized that mutations that are translated into abnormal proteins could affect the transcription of GATA2, triggering GATA2 deficiency. Chromatin immunoprecipitation and luciferase assays showed that the human GATA2 protein activates its own transcription through a specific region located at -2.4 kb, whereas the p.Thr354Met, p.Thr355del, and p.Arg396Gln germline mutations impair GATA2 promoter activation. Accordingly, GATA2 expression was decreased to ∼58% in a patient with p.Arg396Gln, compared with controls. p.Arg396Gln is the second most common mutation in these syndromes, and no previous functional analyses have been performed. We therefore analyzed p.Arg396Gln. Our data show that p.Arg396Gln is a loss-of-function mutation affecting DNA-binding ability and, as a consequence, it fails to maintain the immature characteristics of hematopoietic stem and progenitor cells, which could result in defects in this cell compartment. In conclusion, we show that human GATA2 binds to its own promoter, activating its transcription, and that the aforementioned mutations impair the transcription of GATA2. Our results indicate that they can affect other GATA2 target genes, which could partially explain the variability of symptoms in these diseases. Moreover, we show that p.Arg396Gln is a loss-of-function mutation, which is unable to retain the progenitor phenotype in cells where it is expressed.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25624456     DOI: 10.4049/jimmunol.1401868

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.

Authors:  Zhijie Wu; Shouguo Gao; Carrie Diamond; Sachiko Kajigaya; Jinguo Chen; Rongye Shi; Cindy Palmer; Amy P Hsu; Katherine R Calvo; Dennis D Hickstein; Steven M Holland; Neal S Young
Journal:  Blood Adv       Date:  2020-06-23

2.  GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.

Authors:  Moonjung Jung; Stefan Cordes; Jizhong Zou; Shiqin J Yu; Xavi Guitart; So Gun Hong; Vinh Dang; Elaine Kang; Flavia S Donaires; Sergio A Hassan; Maher Albitar; Amy P Hsu; Steven M Holland; Dennis D Hickstein; Danielle Townsley; Cynthia E Dunbar; Thomas Winkler
Journal:  Blood Adv       Date:  2018-12-11

3.  Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Authors:  Candace L Haddox; Ryan M Carr; Roshini S Abraham; Juliana Perez Botero; Vilmarie Rodriguez; Animesh Pardanani; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2019-06-27

Review 4.  Germline GATA2 Mutation and Bone Marrow Failure.

Authors:  Lisa J McReynolds; Katherine R Calvo; Steven M Holland
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

5.  Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance.

Authors:  Edgar Borges de Oliveira-Júnior; Jérémie Rosain; Franck Rapaport; Caroline Deswarte; Antoine Guérin; Sairaj Munavar Sajjath; Yu Jerry Zhou; Stéphane Marot; Claire Lozano; Aurélie Cobat; Laurent Abel; Jean-Laurent Casanova; Carmen Oleaga-Quintas; Lidia Branco; Nuria Fernández-Hidalgo; Dukhee Betty Lew; Anne-Sophie Brunel; Caroline Thomas; Elise Launay; Andrés Augusto Arias; Alexis Cuffel; Vanesa Cunill Monjo; Anna-Lena Neehus; Laura Marques; Manon Roynard; Marcela Moncada-Vélez; Bengü Gerçeker; Roger Colobran; Marie-Gabrielle Vigué; Gabriela Lopez-Herrera; Laura Berron-Ruiz; Nora Hilda Segura Méndez; Patricia O'Farrill Romanillos; Tom Le Voyer; Anne Puel; Christine Bellanné-Chantelot; Kacy A Ramirez; Lazaro Lorenzo-Diaz; Noé Ramirez Alejo; Rebeca Pérez de Diego; Antonio Condino-Neto; Fethi Mellouli; Carlos Rodriguez-Gallego; Torsten Witte; José Franco Restrepo; Mariana Jobim; Stéphanie Boisson-Dupuis; Eric Jeziorski; Claire Fieschi; Guillaume Vogt; Jean Donadieu; Marlène Pasquet; Julia Vasconcelos; Fatma Omur Ardeniz; Mónica Martínez-Gallo; Regis A Campos; Luiz Fernando Jobim; Rubén Martínez-Barricarte; Kang Liu; Jacinta Bustamante
Journal:  J Clin Immunol       Date:  2021-01-08       Impact factor: 8.317

Review 6.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

7.  Heterozygous variants in GATA2 contribute to DCML deficiency in mice by disrupting tandem protein binding.

Authors:  Atsushi Hasegawa; Yuki Hayasaka; Masanobu Morita; Yuta Takenaka; Yuna Hosaka; Ikuo Hirano; Masayuki Yamamoto; Ritsuko Shimizu
Journal:  Commun Biol       Date:  2022-04-19

8.  Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.

Authors:  C-E Chong; P Venugopal; P H Stokes; Y K Lee; P J Brautigan; D T O Yeung; M Babic; G A Engler; S W Lane; M Klingler-Hoffmann; J M Matthews; R J D'Andrea; A L Brown; C N Hahn; H S Scott
Journal:  Leukemia       Date:  2017-06-23       Impact factor: 11.528

9.  GATA2 deficiency and related myeloid neoplasms.

Authors:  Marcin W Wlodarski; Matthew Collin; Marshall S Horwitz
Journal:  Semin Hematol       Date:  2017-05-10       Impact factor: 3.851

10.  Tumor suppressor function of Gata2 in acute promyelocytic leukemia.

Authors:  Casey D S Katerndahl; Olivia R S Rogers; Ryan B Day; Michelle A Cai; Timothy P Rooney; Nichole M Helton; Mieke Hoock; Sai Mukund Ramakrishnan; Sridhar Nonavinkere Srivatsan; Lukas D Wartman; Christopher A Miller; Timothy J Ley
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.